Kangpu To Present a Case Report of KPG-121 in Combination with Enzalutamide for the Treatment of mCRPC at SITC 2023

Shanghai, China, October 27, 2023 -- Kangpu Biopharmaceuticals, a clinical-stage company focused on the discovery and development of next-generation of immunomodulatory small molecules for the treatments of solid tumors, hematological malignancies, autoimmune diseases as well as inflammatory disorders, announced today that it will present a case report of KPG-121 in combination with enzalutamide for the treatment of metastatic castration resistant prostate cancer (mCRPC) patient with AR F877L mutation at the 2023 Society for Immunotherapy of Cancer Annual Meeting (SITC 2023) to be held in San Diego from November 1-5, 2023.

Abstract Title: A case report of metastatic castration resistant prostate cancer patient with AR F877L mutation treated with KPG-121 in combination with enzalutamide

Abstract Number: 904

Time: 9:00 AM - 8:30 PM Pacific Time, November 4, 2023

0:00 AM – 11:30 AM Beijing Time, November 5, 2023

KPG-121 is a novel modulator of the Cerebron (CRBN) E3 ubiquitin ligase complex CRL4^CRBN targeting rapid ubiquitination and degradation of casein kinase 1A1 (CK1α) and transcription factors Aiolos and Ikaros. KPG-121 promotes anti-proliferation and anti-angiogenesis activities and enhances immunomodulatory properties. KPG-121 significantly improves anti-tumor efficacies when combined with androgen-receptor antagonists including enzalutamide, abiraterone acetate, apalutamide, or darolutamide in xenograft animal models when compared to the androgen-receptor antagonist monotherapy. A phase I study to determine the safety, pharmacokinetics and efficacy of KPG-121 in combination with enzalutamide, abiraterone, or apalutamide in subjects with non-metastatic or metastatic castration-resistant prostate cancer (mCRPC) was completed in the US. The company plans to initiate pivotal clinical trials MRCT phase II/III for mCRPC.

Abstracts and full session details can be found at https://www.sitcancer.org.

About Kangpu Biopharmaceuticals

Kangpu Biopharmaceuticals, Ltd. is a clinical-stage company focused on the discovery and development of innovative small molecules for the treatment of solid tumors, hematologic malignancies, autoimmune diseases, and inflammatory disorders through novel solutions, including targeted protein ubiquitination and degradation. Kangpu has developed a robust pipeline of potential first-in-class and best-in-class drug candidates based on proprietary technology platforms, including NeoMIDES^®, SelPDEiS^®, and X-SYNERGY^®.

For more information, please visit www.KangpuGroup.com.